Desq Long
Sign in

Company

Amylyx Pharmaceuticals, Inc.

AMLX · CIK 0001658551

SEC FORM 4
$932,552.93

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 29,025 shares at $32.1293 per share.

Reporting Person Klee Justin B. · Officer Title Co-Chief Executive Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390506 · filed 2026-09-14 · View filing →

SEC FORM 4
$47,710.33

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 1,439 shares at $33.1552 per share.

Reporting Person Klee Justin B. · Officer Title Co-Chief Executive Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390506 · filed 2026-09-14 · View filing →

SEC FORM 4
$950,040.16

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 29,545 shares at $32.1557 per share.

Reporting Person Cohen Joshua B · Officer Title Co-Chief Executive Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390507 · filed 2026-09-14 · View filing →

SEC FORM 4
$30,463.75

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 919 shares at $33.1488 per share.

Reporting Person Cohen Joshua B · Officer Title Co-Chief Executive Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390507 · filed 2026-09-14 · View filing →

SEC FORM 4
$309,139.59

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 9,525 shares at $32.4556 per share.

Reporting Person Mazzariello Gina · Officer Title Chief Legal Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390508 · filed 2026-09-14 · View filing →

SEC FORM 4
$366.74

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 11 shares at $33.34 per share.

Reporting Person Mazzariello Gina · Officer Title Chief Legal Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390508 · filed 2026-09-14 · View filing →

SEC FORM 4
$315,194.80

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 9,768 shares at $32.2681 per share.

Reporting Person FRATES JAMES M · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390509 · filed 2026-09-14 · View filing →

SEC FORM 4
$34,625.87

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 1,042 shares at $33.2302 per share.

Reporting Person FRATES JAMES M · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390509 · filed 2026-09-14 · View filing →

SEC FORM 4
$256,003.86

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 7,947 shares at $32.2139 per share.

Reporting Person Bedrosian Camille L · Officer Title Chief Medical Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390510 · filed 2026-09-14 · View filing →

SEC FORM 4
$68,864.24

Amylyx Pharmaceuticals, Inc. (AMLX)

Sale of 2,081 shares at $33.0919 per share.

Reporting Person Bedrosian Camille L · Officer Title Chief Medical Officer · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0001193125-26-390510 · filed 2026-09-14 · View filing →

SEC FORM 4
$44,000.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code M) of 25,000 shares at $1.76 per share.

Reporting Person Firestone Karen · Transaction Code M

Traded Aug 31, 2026 · Disclosed Sep 2, 2026

Source: SEC Form 4 · 0001193125-26-380152 · filed 2026-09-02 · View filing →

SEC FORM 4
$126,250.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code M) of 25,000 shares at $5.05 per share.

Reporting Person Firestone Karen · Transaction Code M

Traded Aug 31, 2026 · Disclosed Sep 2, 2026

Source: SEC Form 4 · 0001193125-26-380152 · filed 2026-09-02 · View filing →

SEC FORM 4
$0.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code A) of 60,039 shares at $0 per share.

Reporting Person Cohen Joshua B · Officer Title Co-Chief Executive Officer · Transaction Code A

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001193125-26-359675 · filed 2026-08-20 · View filing →

SEC FORM 4
$0.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code A) of 22,807 shares at $0 per share.

Reporting Person Bedrosian Camille L · Officer Title Chief Medical Officer · Transaction Code A

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001193125-26-359676 · filed 2026-08-20 · View filing →

SEC FORM 4
$0.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code A) of 21,284 shares at $0 per share.

Reporting Person Mazzariello Gina · Officer Title Chief Legal Officer · Transaction Code A

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001193125-26-359677 · filed 2026-08-20 · View filing →

SEC FORM 4
$0.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code A) of 60,039 shares at $0 per share.

Reporting Person Klee Justin B. · Officer Title Co-Chief Executive Officer · Transaction Code A

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001193125-26-359678 · filed 2026-08-20 · View filing →

SEC FORM 4
$0.00

Amylyx Pharmaceuticals, Inc. (AMLX)

Acquisition (code A) of 22,807 shares at $0 per share.

Reporting Person FRATES JAMES M · Officer Title Chief Financial Officer · Transaction Code A

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0001193125-26-359679 · filed 2026-08-20 · View filing →